--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000805498.md" description: "๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: Tempus AI to Acquire Personalis in $๐Ÿ.๐Ÿ“ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง Deal - $Tempus AI(TEM.US) $Personalis(PSNL.US) ๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โžค ๐“๐ž๐ฆ๐ฉ๐ฎ๐ฌ ๐€๐ˆ will acquire ๐๐ž๐ซ๐ฌ๐จ๐ง๐š๐ฅ๐ข๐ฌ in a $๐Ÿ.๐Ÿ“ ๐›๐ข๐ฅ๐ฅ๐ข๐จ๐ง transaction.โžค Personalis shareholders will receive $๐Ÿ๐Ÿ”.๐Ÿ๐Ÿ“ per common share.โžค Acquisition expands Tempus' ๐ฆ๐ข๐ง๐ข๐ฆ๐š๐ฅ ๐ซ๐ž๐ฌ๐ข๐๐ฎ๐š๐ฅ ๐๐ข๐ฌ๐ž๐š๐ฌ (๐Œ๐‘๐ƒ) capabilities.โžค Deal combines Personalis' MRD technology with Tempus' ๐€๐ˆ and multimodal data platform.โžค Tempus says MRD represents a $๐Ÿ๐ŸŽ ๐›๐ข๐ฅ๐ฅ๐ข๐จ๐ง market opportunity.โžค Companies have partnered since ๐๐จ๐ฏ๐ž๐ฆ๐›๐ž๐ซ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ‘.โžค Personalis' NeXT Personalยฎ test offers ๐ฎ๐ฅ๐ญ๐ซ๐š๐ฌ๐ž๐ง๐ฌ๐ข๐ญ๐ข๐ฏ๐ž cancer recurrence monitoring.โžค Medicare currently covers the test in ๐ญ๐ก๐ซ๐ž๐ž indications.โžค Acquisition aims to expand personalized cancer monitoring and biomarker discovery.๐Ÿ‘‰ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ๐ฌ:๐„๐ซ๐ข๐œ ๐‹๐ž๐Ÿ๐ค๐จ๐Ÿ๐ฌ๐ค๐ฒ, CEO of Tempus:โ€œMRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs. Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."๐‚๐ก๐ซ๐ข๐ฌ ๐‡๐š๐ฅ๐ฅ, CEO of Personalis:โ€œWe believe this transaction represents an exciting next chapter for Personalis. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners. After conducting an exhaustive process, we are confident Tempusโ€™ offer provides the most value to our shareholders and the fastest path to bringing Personalisโ€™ industry-leading tests to patients suffering from cancer.โ€" datetime: "2026-07-20T12:32:03.000Z" locales: - [en](https://longbridge.com/en/topics/100000000805498.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000805498.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000805498.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" generator: "portal-rs" --- # ๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: Tempus AI to Acquire Personalis in $๐Ÿ.๐Ÿ“โ€ฆ ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**